<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910114-0050</DOCNO><DOCID>910114-0050.</DOCID><HL>   Technology Brief -- Progenics Pharmaceuticals Inc.:   Firm, Du Pont Sign Pact   On Drug-Screening System</HL><DATE>01/14/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C17</SO><CO>   DD</CO><IN>DRUG MANUFACTURERS (DRG)</IN><LP>   Progenics Pharmaceuticals Inc. said it signed an agreementwith Du Pont Co. to develop and market Nenquest, adrug-screening system that has the potential to identify thehuman immunodeficiency virus, which causes AIDS.   Under the agreement, the Tarrytown, N.Y.,biopharmaceutical company will supply CD4, a protein found onthe surface of human target cells, for use in the screeningsystems, which Du Pont will develop, assemble and market.Progenics said it will receive royalties of more than 10% onthe final product and payment for supplying CD4.</LP><TEXT/></DOC>